Harvey Capital Management Inc Nektar Therapeutics Transaction History

Harvey Capital Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 31, 2019	SELL	$30.43 - $56.65 $152,150 - $283,250	-5,000 Closed	0 $0
Q3 2018 Oct 24, 2018	SELL	$46.46 - $68.49 $1.26 Million - $1.86 Million	-27,215 Reduced 84.48%	5,000 $304,000
Q2 2018 Aug 07, 2018	SELL	$46.25 - $104.45 $1.45 Million - $3.27 Million	-31,260 Reduced 49.25%	32,215 $1.57 Million
Q1 2018 Apr 27, 2018	SELL	$57.4 - $108.44 $5.5 Million - $10.4 Million	-95,835 Reduced 60.16%	63,475 $6.74 Million
Q4 2017 Feb 02, 2018	SELL	$23.02 - $60.5 $2.94 Million - $7.74 Million	-127,890 Reduced 44.53%	159,310 $9.51 Million

Q3 2017 Nov 08, 2017	BUY	$17.79 - $24.0 $5.11 Million - $6.89 Million	287,200	287,200 $6.89 Million

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Harvey Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Harvey Capital Management Inc with notifications on news.